[Hypotensive efficacy and tolerability of combination of dihydropyridine and non-dihydropyridine calcium antagonists in the treatment of patients with arterial hypertension].
Iskenderov
B G
BG
Penza, Russia.
Burmistrova
L F
LF
Berenshteĭn
N V
NV
Lokhina
T V
TV
D000328:Adult; D002121:Calcium Channel Blockers / Q000009:adverse effects* / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology; D004095:Dihydropyridines / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000453:epidemiology; D006973:Hypertension / Q000188:drug therapy* / Q000453:epidemiology; D017379:Hypertrophy, Left Ventricular / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000009:adverse effects* / Q000627:therapeutic use*; D009765:Obesity / Q000453:epidemiology; D016896:Treatment Outcome; D014700:Verapamil / Q000009:adverse effects* / Q000627:therapeutic use*
D002121:Calcium Channel Blockers; D004095:Dihydropyridines; C038806:1,4-dihydropyridine; D014700:Verapamil; D009543:Nifedipine